The fundamental basis of inflammatory bowel disease

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 514-521

  Strober, Warren ^a,b   Fuss, Ivan ^a   Mannon, Peter ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ALICAFORSEN; BASILIXIMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FONTOLIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40; INTERLEUKIN 12P40 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MLN 02; NATALIZUMAB; UNCLASSIFIED DRUG; VISILIZUMAB;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; EPITHELIUM CELL; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MICROFLORA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA;

EID: 33847381116     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30587     Document Type: Article

References (83)

1. Podolsky, D. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347:417-429.
2. Fuss, I., et al. 2004. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490-1497. doi:10.1172/JCI200419836.
3. McLeod, R. 2003. Surgery for inflammatory bowel diseases. Dig. Dis. 21:168-179.
4. Feagan, B. 2003. Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98(Suppl. 12):S6-S17.
5. Sandborn, W. 2006. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev. Gastroenterol. Disord. 6:97-105.
6. Siegel, C., and Sands, B. 2005. Practical management of inflammatory bowel disease patients taking immunomodulators. Aliment. Pharmacol. Ther. 22:1-16.
7. Targan, S. 2006. Current limitations of IBD treatment: where do we go from here? Ann. N. Y. Acad. Sci. 1072:1-8.
8. Fuss, I., et al. 2006. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12:9-15.
9. Yen, D., et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316. doi:10.1172/JCI21404.
10. Mannon, P., et al. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351:2069-2079.
11. Schappi, M., et al. 2003. The nature of colitis in chronic granulomatous disease. J. Pediatr. Gastroenterol. Nutr. 36:623-631.
12. Mannon, P., et al. 2006. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 131:748-756.
13. Hussain, N., et al. 2006. Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and distribution with genotype. Clin. Gastroenterol. Hepatol. 4:73-80.
14. Phan, G., et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100:8372-8377.
15. Duchmann, R., Herman, E., Mayet, W., Ewe, K., and Meyer zum Buschenfelde, K.H. 1995. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102:448-455.
16. Strober, W., Fuss, I., and Blumberg, R. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20:495-549.
17. Hermiston, M., and Gordon, J. 1995. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 270:1203-1207.
18. Inohara, N., and Nunez, G. 2003. NODS: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3:371-382.
19. Strober, W., Murray, P., Kitani, A., and Watanabe, T. 2006. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6:9-20.
20. Kobayashi, M., et al. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111:1297-1308. doi:10.1172/JCI200317085.
21. Rakoff-Nahoum, S., Hao, L., and Medzhitov, R. 2006. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity. 25:319-329.
22. Hugot, J., et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:599-603.
23. Ogura, Y., et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:603-606.
24. Watanabe, T., Kitani, A., Murray, P., and Strober, W. 2004. NOD2 is a negative regulator of Toll-like receptor2-mediated T helper type 1 responses. Nat. Immunol. 5:800-808.
25. Kobayashi, K., et al. 2002. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature. 416:194-199.
26. Abbott, D., Wilkins, A., Asara, J., and Cantley, L. 2004. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14:2217-2227.
27. Uehara, A., et al. 2005. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2 and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell. Microbiol. 7:53-61.
28. Zelinkova, Z., et al. 2005. Functional consequences of NOD2 deficiency in Crohn's disease patients peripheral blood blood monocytes derived dendritic cells. Gastroenterology. 128:A510.
29. Watanabe, T., et al. 2006. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity. 25:473-485.
30. Iqbal, N., et al. 2002. T helper 1 and T helper 2 cells are pathogenic in an antigen specific model of colitis. J. Exp. Med. 195:71-84.
31. Yoshida, M., et al. 2001. CD4 T cells monospecific to ovalbumin produced by Eschericia coli can induce colitis upon transfer to BALB/c and SCID mice. Int. Immunol. 13:1561-1570.
32. Lodes, M., et al. 2004. Bacterial flagellin is a dominant antigen in Crohn's disease. J. Clin. Invest. 113:1296-1306. doi:10.1172/JCI200420295.
33. Elson, C., and Cong, Y. 2002. Understanding immune-microbial homeostasis in intestine. Immunol. Res. 26:87-94.
34. Brandwein, S., et al. 1997. Spontaneous colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J. Immunol. 159:44-52.
35. Cong, Y., et al. 1998. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187:855-864.
36. Robinson, W., et al. 2003. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalitis. Nat. Biotechnol. 21:1017-1019.
37. Targan, S., et al. 2005. Antibodies to CBirt flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 128:2020-2028.
38. Beckwith, J., Cong, Y., Sundberg, J., Elson, C., and Leiter, E. 2005. Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune responses to enteric bacterial antigens. Gastroenterology. 129:1473-1484.
39. Swidsinski, A., et al. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology. 122:44-54.
40. Darfeuille-Michaud, A., et al. 1998. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohns' disease. Gastroenterology. 115:1405-1413.
41. Martin, H., et al. 2004. Enhanced Eschericia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 127:80-93.
42. Bibiloni, R., Mangold, M., Madsen, K., Fedorak, R., and Tannock, G. 2006. The bacteriology of biopsies differs between newly diagnosed, untreated Crohn's disease and ulcerative colitis patients. J. Med. Microbiol. 55:1141-1149.
43. Prindiville, T., Cantrell, M., and Wilson, K. 2004. Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. Inflamm. Bowel Dis. 10:824-833.
44. Seksik, P., et al. 2006. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease Aliment. Pharmacol. Ther. 24:11-18.
45. Niewenhuis, E. 2006. CD1d-dependent regulation of bacterial colonization in the intestine. Gastroenterology. 130:A61.
46. Wehkamp, J., et al. 2005. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. U. S. A. 102:18129-18134.
47. Wehkamp, J., et al. 2003. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 9:215-223.
48. Fellerman, K., et al. 2006. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn's disease in the colon. Am. J. Hum. Genet. 79:439-448.
49. Hisamatsu, T., et al. 2003. CARD15/NOD2 functions as an antibacterial factor in human epithelial cells. Gastroenterology. 124:1145-1149.
50. Kobayashi, K.S., et al. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 307:731-734.
51. Niess, J., et al. 2005. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 307:254-258.
52. Rescigno, M., et al. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2:361-367.
53. Macpherson, A., and Uhr, T. 2004. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 303:1662-1665.
54. Mantis, N., et al. 2002. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J. Immunol. 169:1844-1851.
55. DiGiacinto, C., Marinaro, M., Sanchez, M., Strober, W., and Boirivant, M. 2005. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells. J. Immunol. 174:3237-3246.
56. Wilson, C., et al. 1999. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 286:113-117.
57. Norkina, O., Burnett, T., and Lisle, R.D. 2004. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect. Immun. 72:6040-6049.
58. Ho, G., et al. 2006. ABC1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum. Mol. Genet. 15:797-805.
59. Newman, B., et al. 2005. A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology. 128:260-269.
60. Panwala, C., Jones, J., and Viney, J. 1998. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:5733-5744.
61. Peltekova, V., et al. 2004. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. 36:471-475.
62. Adelman, B., Sandrock, A., and Panzara, M. 2005. Natalizumab and progressive multifocal leukoencephalopathy. N. Engl. J. Med. 353:432-433.
63. Blonski, W., and Lichtenstein, G. 2006. Complications of biological therapy for inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22:30-43.
64. Feagan, B., et al. 2005. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352:2499-2507.
65. Hanauer, S., et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:1541-1549.
66. Rutgeerts, P., et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353:2462-2476.
67. Sandborn, W., et al. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353:1912-1925.
68. Hommes, D., et al. 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 55:1131-1137.
69. Ito, H., et al. 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 126:989-996.
70. Braat, H., et al. 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4:754-759.
71. Nishioka, C., et al. 2005. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J. Gastroenterol. Hepatol. 20:1567-1571.
72. Sands, B., et al. 2006. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J. Clin. Gastroenterol. 40:482-489.
73. Targan, S., et al. 2005. A phase I-II Study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC). Gastroenterology. 128:A75.
74. Oyama, Y., et al. 2005. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 128:552-563.
75. Reinisch, W., et al. 2001. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment. Pharmacol. Ther. 15:1313-1322.
76. Garcia-Olmo, D., et al. 2005. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum. 48:1416-1423.
77. Korzenik, J., Dieckgraefe, B., Valentine, J., Hausman, D., and Gilbert, M.J. 2005. Sargramostim for active Crohn's disease. N. Engl. J. Med. 352:2193-2201.
78. Weinstock, J. 2006. Helminths and mucosal immune modulation. Ann. N. Y. Acad. Sci. 1072:356-364.
79. Creed, T., Norman, M., and Probert, C. 2003. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. 18:65-75.
80. Van Assche, G., et al. 2006. Daclizumab, a humanized monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial. Gut. 55:1568-1574.
81. Van Deventer, S., Volfova, M., and Flisiak, R. 2005. A phase 2 dose-ranging, double blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Gastroenterology. 128:A74.
82. Sinha, A., Nightingale, J., West, K., Berlanga-Acosta, J., and Playford, R. 2003. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-Sided ulcerative colitis or proctitis. N. Engl. J. Med. 349:350-357.
83. Summers, R., Elliott, D., and Urban, J. 2005. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 128:825-832.